2025 China Innovative Drug Asset Transaction Overview
- 2025 marked both “volume growth” and a “value explosion.” While cross-border deal count grew 18% y/y to 136 deals, aggregate upfront value increased at a faster pace than deal volume growth—total China-related licensing and acquisition value reached ~$7.1B (vs. $4.0B in 2024), with average upfront value nearly doubling from $56M (2022) to $116M (2025). For deals with >$100M upfront, China-originated assets accounted for 36% of global deals in 2025, up from 26% in 2024.
- Out-licensing (OL) is now the strategic centerpiece, driven by MNC patent-cliff pressure and China’s maturing innovation. MNCs are no longer “bargain hunting”; instead, they are strategically sourcing de-risked, best-in-class assets at scale. The deal mix is shifting toward earlier stages, with ~60% of cross-border transactions involving preclinical or Phase 1 assets, reflecting growing global trust in China’s discovery capabilities.
- Modality and therapeutic area diversification is accelerating beyond oncology ADCs. Among the 26 out-licensing deals exceeding $50M upfront in 2025, next-generation antibodies (bi/tri-specifics and nanobodies) and ADCs each accounted for about 30%, while CVRM (cardiovascular, renal, and metabolic diseases) is emerging as a high-growth vertical. Domestic deals rebounded 14% y/y in volume, and CROs are moving from supporting roles to more prominent positions.
- In-licensing (IL) transactions showed mixed trends in 2025, with deal volume declining 40% to 21 transactions, while total upfront payments rebounded 109% to $92M after three consecutive years of decline. Zai Lab, once a benchmark for China’s license-in model, completed two deals in 2025, potentially signaling the market has bottomed out.
- 2026 Outlook: OL deal values are set to climb further, but the “bargain basement” era is over; IL deals are expected to recover. Early 2026 data shows average OL upfront values at ~$160M, already over 30% above 2025 levels. We expect antibody-focused deals to persist, while CGT assets emerge as the next frontier. Overall momentum is expected to sustain through at least H1 2027, supported by a looming $300B+ global patent cliff. China pharma companies are also expected to become more active in in-licensing, driven by easing IPO restrictions and a recovery in capital markets in Hong Kong and mainland China.
We invite you to explore our latest report and welcome the opportunity to discuss its key insights with you.
Upcoming Event:
27th April 2026
Contact us:
Headquarter office
3F, 1305 South Suzhou Road
Shanghai, China
wxiang@yafocapital.com
BioToChina.org 